Moreover, tumours treated with PTX/PEG2k-Fmoc-NLG(L) had more granzyme B-producing CD8+ T cells than the tumours treated with Taxol, suggesting IDO inhibition can still enhance antitumour T-cell immune responses in spite of repeated chemotherapy. This evidence concerns the gene IDO1 and neoplasm.